Johnson and Johnson (JNJ) 銘柄情報

U.S. Stocks Move Sharply Higher, Dow Reaches One-Month Closing High

Stocks showed a strong move to the upside during trading on Friday, with the major averages more than offsetting the losses posted in the previous session. With the upward move, the Dow ended the...

New Drug Application initiated with U.S. FDA for TAR-200, the first and only intravesical drug releasing system for patients with BCG-unresponsive high-risk non-muscle-invasive bladder cancer

New Drug Application initiated with U.S. FDA for TAR-200, the first and only intravesical drug releasing system for patients with BCG-unresponsive high-risk non-muscle-invasive bladder cancer PR...

Form DFAN14A - Additional definitive proxy soliciting materials filed by non-management and Rule 14(a)(12) material

Johnson & Johnson Strengthens Neuroscience Leadership with Acquisition of Intra-Cellular Therapies, Inc.

Acquisition includes CAPLYTA® (lumateperone), the first and only U.S. FDA-approved treatment for bipolar I and II depression as an adjunctive and monotherapy; also approved for the treatment of...

Johnson & Johnson Strengthens Neuroscience Leadership with Acquisition of Intra-Cellular Therapies, Inc.

Acquisition includes CAPLYTA® (lumateperone), the first and only U.S. FDA-approved treatment for bipolar I and II depression as an adjunctive and monotherapy; also approved for the treatment of...

Nipocalimab granted U.S. FDA Priority Review for the treatment of generalized myasthenia gravis

Nipocalimab granted U.S. FDA Priority Review for the treatment of generalized myasthenia gravis PR Newswire SPRING HOUSE, Pa., Jan. 9, 2025 Biologics License Application acceptance supported by...

Johnson & Johnson's Posdinemab and Tau Active Immunotherapy Receive U.S. FDA Fast Track Designations for the Treatment of Alzheimer's Disease

Johnson & Johnson's Posdinemab and Tau Active Immunotherapy Receive U.S. FDA Fast Track Designations for the Treatment of Alzheimer's Disease PR Newswire TITUSVILLE, N.J., Jan. 8, 2025...

RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE™ (lazertinib) show statistically significant and clinically meaningful improvement in overall survival versus osimertinib

RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE™ (lazertinib) show statistically significant and clinically meaningful improvement in overall survival versus osimertinib PR Newswire RARITAN, N.J...